Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, EYPT, ACLX, ALPN, BBIO, and represent 39.44% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: CRBP (+$80M), PRAX (+$41M), NAMS (+$36M), Cg Oncology (+$35M), MRUS (+$32M), Helix Acquisition Corp Ii Cl A (+$30M), BHVN (+$29M), TRML (+$29M), JANX (+$28M), LBPH (+$22M).
- Started 19 new stock positions in CMPX, Arrivent Biopharma, VTYX, BEAM, SLN, ENGN, NKTX, JANX, Cg Oncology, CRBP. Kyverna Therapeutics, ATXS, MRUS, ARQT, MRSN, TRML, Helix Acquisition Corp Ii Cl A, NAMS, CABA.
- Reduced shares in these 10 stocks: Ambrx Biopharma (-$160M), Rayzebio (-$75M), IMVT (-$49M), Cymabay Therapeutics (-$43M), OLMA (-$35M), SYRE (-$26M), SNDX (-$25M), Harpoon Therapeutics (-$23M), AXNX (-$16M), APLS (-$13M).
- Sold out of its positions in AXNX, Cymabay Therapeutics, EDIT, Harpoon Therapeutics, IMVT, NMRA, Ambrx Biopharma, OLMA, Rayzebio, SNDX.
- Cormorant Asset Management was a net buyer of stock by $70M.
- Cormorant Asset Management has $2.3B in assets under management (AUM), dropping by 8.87%.
- Central Index Key (CIK): 0001583977
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 57 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 18.7 | $427M | 8.5M | 50.23 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 6.3 | $143M | +14% | 6.9M | 20.67 |
|
| Arcellx Common Stock (ACLX) | 5.4 | $124M | +4% | 1.8M | 69.55 |
|
| Alpine Immune Sciences (ALPN) | 4.7 | $107M | +5% | 2.7M | 39.64 |
|
| Bridgebio Pharma (BBIO) | 4.3 | $99M | -4% | 3.2M | 30.92 |
|
| Praxis Precision Medicines I Com New (PRAX) | 3.5 | $80M | +106% | 1.3M | 61.02 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 3.5 | $80M | NEW | 2.0M | 39.24 |
|
| Tarsus Pharmaceuticals (TARS) | 3.4 | $78M | -3% | 2.1M | 36.35 |
|
| Longboard Pharmaceuticals In (LBPH) | 3.2 | $72M | +42% | 3.4M | 21.60 |
|
| Edgewise Therapeutics (EWTX) | 2.4 | $55M | +17% | 3.0M | 18.24 |
|
| Crinetics Pharmaceuticals In (CRNX) | 2.4 | $54M | 1.2M | 46.81 |
|
|
| Biomea Fusion (BMEA) | 2.3 | $53M | 3.6M | 14.95 |
|
|
| Korro Bio (KRRO) | 2.1 | $48M | 529k | 90.00 |
|
|
| Vaxcyte (PCVX) | 2.1 | $47M | +3% | 685k | 68.31 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.9 | $42M | +21% | 6.6M | 6.38 |
|
| Pharvaris N V (PHVS) | 1.7 | $40M | 1.7M | 23.11 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.6 | $36M | NEW | 1.5M | 23.65 |
|
| Cg Oncology | 1.5 | $35M | NEW | 800k | 43.90 |
|
| Alx Oncology Hldgs (ALXO) | 1.5 | $35M | 3.1M | 11.15 |
|
|
| Biohaven (BHVN) | 1.5 | $34M | +652% | 617k | 54.69 |
|
| Merus N V (MRUS) | 1.4 | $32M | NEW | 715k | 45.03 |
|
| Aerovate Therapeutics (AVTE) | 1.4 | $32M | -11% | 1.1M | 29.57 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.3 | $31M | 2.1M | 14.30 |
|
|
| Helix Acquisition Corp Ii Cl A Ord Shs | 1.3 | $30M | NEW | 2.9M | 10.40 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 1.3 | $29M | 3.3M | 9.04 |
|
|
| Tourmaline Bio (TRML) | 1.3 | $29M | NEW | 1.3M | 22.90 |
|
| Janux Therapeutics (JANX) | 1.2 | $28M | NEW | 750k | 37.65 |
|
| Neurogene (NGNE) | 1.2 | $27M | -27% | 539k | 50.90 |
|
| Cargo Therapeutics (CRGX) | 1.2 | $26M | 1.2M | 22.32 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 1.0 | $24M | 550k | 43.33 |
|
|
| Apellis Pharmaceuticals (APLS) | 1.0 | $24M | -36% | 400k | 58.78 |
|
| Arcutis Biotherapeutics (ARQT) | 0.9 | $21M | NEW | 2.1M | 9.91 |
|
| Ideaya Biosciences (IDYA) | 0.9 | $20M | 450k | 43.88 |
|
|
| Cabaletta Bio (CABA) | 0.8 | $19M | NEW | 1.1M | 17.06 |
|
| Astria Therapeutics (ATXS) | 0.8 | $18M | NEW | 1.3M | 14.07 |
|
| Engene Holdings (ENGN) | 0.7 | $17M | NEW | 1.0M | 16.95 |
|
| Insmed Com Par $.01 (INSM) | 0.7 | $16M | 575k | 27.13 |
|
|
| Ventyx Biosciences (VTYX) | 0.7 | $15M | NEW | 2.7M | 5.50 |
|
| Nkarta (NKTX) | 0.6 | $15M | NEW | 1.4M | 10.81 |
|
| Silence Therapeutics Ads (SLN) | 0.6 | $14M | NEW | 625k | 21.60 |
|
| Mersana Therapeutics (MRSN) | 0.5 | $12M | NEW | 2.6M | 4.48 |
|
| Compass Therapeutics (CMPX) | 0.5 | $11M | NEW | 5.6M | 1.98 |
|
| Kyverna Therapeutics | 0.5 | $11M | NEW | 440k | 24.84 |
|
| Beam Therapeutics Put Option (BEAM) | 0.4 | $9.9M | NEW | 300k | 33.04 |
|
| Immuneering Corp Class A Com (IMRX) | 0.4 | $9.5M | -21% | 3.3M | 2.89 |
|
| Spyre Therapeutics Com New (SYRE) | 0.4 | $9.5M | -73% | 250k | 37.93 |
|
| Arrivent Biopharma | 0.4 | $9.2M | NEW | 515k | 17.86 |
|
| Rocket Pharmaceuticals (RCKT) | 0.4 | $8.1M | -33% | 300k | 26.94 |
|
| Disc Medicine (IRON) | 0.3 | $7.8M | 125k | 62.26 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.3 | $6.3M | 562k | 11.30 |
|
|
| Gh Research Ordinary Shares (GHRS) | 0.3 | $6.3M | 593k | 10.66 |
|
|
| Stoke Therapeutics (STOK) | 0.3 | $5.8M | -60% | 427k | 13.50 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.2 | $4.7M | 75k | 62.24 |
|
|
| Verve Therapeutics (VERV) | 0.2 | $4.6M | 350k | 13.28 |
|
|
| Rapt Therapeutics (RAPT) | 0.2 | $4.5M | 497k | 8.98 |
|
|
| Vyne Therapeutics (VYNE) | 0.2 | $4.3M | 1.4M | 3.07 |
|
|
| Bioatla (BCAB) | 0.2 | $4.0M | 1.2M | 3.44 |
|
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2024 Q1 filed May 15, 2024
- Cormorant Asset Management 2023 Q4 filed Feb. 14, 2024
- Cormorant Asset Management 2023 Q3 filed Nov. 14, 2023
- Cormorant Asset Management 2023 Q2 filed Aug. 14, 2023
- Cormorant Asset Management 2023 Q1 filed May 15, 2023
- Cormorant Asset Management 2022 Q4 filed Feb. 14, 2023
- Cormorant Asset Management 2022 Q3 filed Nov. 14, 2022
- Cormorant Asset Management 2022 Q2 filed Aug. 15, 2022
- Cormorant Asset Management 2022 Q1 filed May 16, 2022
- Cormorant Asset Management 2021 Q4 filed Feb. 14, 2022
- Cormorant Asset Management 2021 Q3 filed Nov. 15, 2021
- Cormorant Asset Management 2021 Q2 filed Aug. 16, 2021
- Cormorant Asset Management 2021 Q1 filed May 17, 2021
- Cormorant Asset Management 2020 Q4 filed Feb. 16, 2021
- Cormorant Asset Management 2020 Q3 filed Nov. 16, 2020
- Cormorant Asset Management 2020 Q2 filed Aug. 14, 2020